• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
Type 2 Diabetes Mellitus (T2DM) to improve glycemic control
May be used in combination with other antidiabetic agents
To reduce risk of cardiovascular death in adults with T2DM and established cardiovascular disease
Pharmacology:
Empagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor. It reduces renal glucose reabsorption and increases urinary glucose excretion, thereby lowering plasma glucose levels.
Dosage:
Recommended starting dose: 10 mg once daily
May be increased to 25 mg once daily if additional glycemic control is needed
Dose adjustment not required for mild renal impairment
Administration:
Oral administration, preferably in the morning
Can be taken with or without food
Interaction:
Diuretics: May enhance the risk of dehydration
Insulin or insulin secretagogues: Risk of hypoglycemia
May interact with lithium and increase its toxicity
Monitor with blood pressure-lowering agents due to volume depletion
Contraindications:
Hypersensitivity to Empagliflozin
Severe renal impairment, end-stage renal disease, or dialysis
Type 1 diabetes mellitus
History of diabetic ketoacidosis (DKA)
Side Effects:
Urinary tract infections, genital mycotic infections
Dehydration, hypotension
Increased urination, dizziness
Rare: ketoacidosis, acute kidney injury
Pregnancy & Lactation:
Not recommended during second and third trimesters
Avoid during breastfeeding due to potential adverse effects on renal development in infants
Precautions & Warnings:
Monitor renal function and fluid status
Caution in elderly patients and those on diuretics
Educate patient about signs of urinary tract infections or ketoacidosis
Not recommended for type 1 diabetes or for diabetic ketoacidosis
Therapeutic Class:
SGLT2 Inhibitors (Sodium-glucose cotransporter 2 inhibitors)
Storage Conditions:
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.